Results 151 to 160 of about 163,010 (261)

Corrigendum to "Systematic post-translational modification genome wide identifies therapeutic targets for Alzheimer's disease: evidence from multi-cohort analysis" [J Prev Alzheimer Dis, 13 (2026) 100422]. [PDF]

J Prev Alzheimers Dis
Wang X, Liu Y, Fu J, Li Y, Zhao M, Tian Q.   +5 more
europepmc   +1 more source

Engineering Neuronal Network Connectivity Through Precise and Scalable Electrical Modulation

Advanced Science, EarlyView.
This study presents a scalable all‐electrical method for precise neuronal‐circuit reconfiguration based on high‐density microelectrode arrays. By employing biologically inspired plasticity rules, targeted connectivity changes were successfully induced and quantified across diverse neuronal preparations.
Sreedhar S. Kumar, Yannaël Bossard, Rachel Sava, Tobias Gänswein, Lorenca Sadiraj, Jean‐Samuel Dupré, Manuel Schröter, J. Gray Camp, Fernando Cardes, Julian Bartram, Andreas Hierlemann   +10 more
wiley   +1 more source

Provider and patient perspectives on the diagnosis and treatment of Alzheimer's disease: A global perspective from the Global Alzheimer's Leadership Series (GoALS). [PDF]

Alzheimers Dement
Amouyel P, Andrieu S, Bradshaw A, Carmona RC, Dumont M, Grinberg LT, Iwatsubo T, Hansson O, Jack CR, Jicha GA, Mahinrad S, McDade E, Mummery CJ, Petersen RC, Robinson S, Schneider JA, Shellcross L, Smith AG, Snyder HM, Tapply B, Teunissen C, van der Flier WM, Vellas B, Wallon D, Williamson JD, Wilcock D, Carrillo MC.   +26 more
europepmc   +1 more source

A Skull Bone Marrow‐to‐Brain Axis Links Osteoblastic Activity to Myeloid Cell Trafficking, Cerebral Blood Flow, and Cognition in Alzheimer's Progression

Advanced Science, EarlyView.
This study reveals that Alzheimer's disease–linked APP expression in bone‐forming cells drives skull bone marrow remodeling and alters its vascular connections to the brain. These changes disrupt immune cell trafficking, cerebral blood flow, and cognition. Targeting bone marrow macrophages restores brain function, highlighting a previously unrecognized
Lei Xiong, Dong Sun, Hao‐Han Guo, Daehoon Lee, Zhipeng Liu, Lin Mei, Wen‐Cheng Xiong   +6 more
wiley   +1 more source

Global trends in Alzheimer's disease randomized controlled trials: a bibliometric analysis. [PDF]

Dement Neuropsychol
Hosseinpoor-Dashatani S, Ebrahimi N.
europepmc   +1 more source

Diffusion‐Based Generative Model With Scaffold‐Hopping Strategy Yields Highly Potent Bioactive Molecules

Advanced Science, EarlyView.
SMarT‐Diff introduces a multi‐objective generative paradigm that integrates scaffold hopping with structure‐aware scoring to enable controlled exploration beyond the training distribution. The framework consistently balances drug‐likeness, synthesizes accessibility and bioactivity, yielding chemically diverse candidates with enhanced properties.
Yuwei Yang, Xiaoqing Gong, Shukai Gu, Jing Li, Bo Liu, Yanan Tian, Qianqian Zhang, Xiaojun Yao, Huanxiang Liu   +8 more
wiley   +1 more source

Ciclopirox Olamine Inhibits the NLRP3 Inflammasome to Alleviate Inflammatory Diseases

Advanced Science, EarlyView.
There is no drug targeting the NLRP3 inflammasome that has been approved for use in clinical settings. Ciclopirox olamine (CPX), an antifungal agent approved by the US Food and Drug Administration (FDA), is identified as a specific and potent NLRP3 inflammasome inhibitor. CPX targets the NACHT domain of NLRP3 at Y381 to impair NLRP3 oligomerization and
Xinyu Xia, Hui You, Ke Zhang, Hui Jiang, Hongping Liu, Lianghua Liu, Aijie Zhang, You Zhou   +7 more
wiley   +1 more source

Plasma eMTBR-tau243 and %p-tau217 for Biological Staging of Alzheimer Disease.

JAMA Neurol
Salvadó G, Horie K, Barthélemy NR, Schindler SE, Janelidze S, Orduña Dolado A, Bali D, Perrin RJ, Morris JC, Benzinger TLS, Gordon BA, Stomrud E, Mattsson-Carlgren N, Palmqvist S, Vogel JW, Bateman RJ, Ossenkoppele R, Hansson O.   +17 more
europepmc   +1 more source

A framework of digital biomarkers for neurodegenerative diseases. [PDF]

Nat Rev Bioeng
Nerrise F, Schütz N, Zhao Q, Gould C, Milstein A, Schulman K, Henderson VW, Landay J, Fei-Fei L, Lin FV, Adeli E.   +10 more
europepmc   +1 more source

Targeting PLD3 Reverses the Immunosuppressive Niche by Reprogramming Tumor‐Associated Macrophages and Potentiates Antitumor Immunity

Advanced Science, EarlyView.
PLD3 activates the lysosomal‐AKT‐NF‐κB axis to drive cellular senescence in macrophages, establishing an immunosuppressive TME by limiting the infiltration of cytotoxic T, NK, and NKT cells, which confers resistance to anti‐PD‐1 therapy. Abrine inhibits PLD3 expression, restoring antitumor immunity and synergizing with anti‐PD‐1 treatment.
Xingtu Qin, Qiong Li, Xuemei Xu, Yuhan Wu, Yin Zhu, Jieqiong Wu, Yuan Fang, Qiubei Chen, Shuyang Wang, Jiang Yu, Yaping Ye, Hongli Jiao   +11 more
wiley   +1 more source